Cordlife Group Limited (CLIFF)
USD 0.3
(0.0%)
USD 0.3
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 92.8 Million SGD | -0.92% |
| 2022 | 93.66 Million USD | 30.27% |
| 2021 | 71.9 Million SGD | -4.96% |
| 2020 | 75.65 Million SGD | 7.09% |
| 2019 | 70.64 Million SGD | -20.55% |
| 2018 | 88.92 Million SGD | -8.08% |
| 2017 | 96.74 Million SGD | 31.8% |
| 2016 | 73.4 Million SGD | -46.74% |
| 2015 | 137.81 Million SGD | 8.51% |
| 2014 | 127 Million SGD | 157.02% |
| 2013 | 49.41 Million SGD | 15.22% |
| 2012 | 42.88 Million SGD | 123.32% |
| 2011 | 19.2 Million SGD | 29.43% |
| 2010 | 14.83 Million SGD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q1 | 98.02 Million SGD | 40.44% |
| 2023 Q2 | 72.44 Million USD | -26.09% |
| 2023 Q4 | 70.29 Million USD | -24.26% |
| 2023 FY | 92.8 Million SGD | -0.92% |
| 2023 Q3 | 92.8 Million SGD | 28.1% |
| 2022 Q1 | 93.47 Million SGD | -3.66% |
| 2022 FY | 93.66 Million USD | 30.27% |
| 2022 Q4 | 69.8 Million USD | -25.48% |
| 2022 Q3 | 93.66 Million SGD | 39.37% |
| 2022 Q2 | 67.2 Million SGD | -28.1% |
| 2021 Q1 | 95.05 Million SGD | -4.94% |
| 2021 Q3 | 97.02 Million SGD | 2.07% |
| 2021 Q4 | 97.02 Million SGD | 0.0% |
| 2021 FY | 71.9 Million SGD | -4.96% |
| 2021 Q2 | 95.05 Million SGD | 0.0% |
| 2020 Q2 | 101.02 Million SGD | 0.0% |
| 2020 Q3 | 99.99 Million SGD | -1.02% |
| 2020 Q4 | 99.99 Million SGD | 0.0% |
| 2020 FY | 75.65 Million SGD | 7.09% |
| 2020 Q1 | 101.02 Million SGD | 6.34% |
| 2019 Q4 | 94.99 Million SGD | -1.06% |
| 2019 Q1 | 95.3 Million SGD | 7.17% |
| 2019 FY | 70.64 Million SGD | -20.55% |
| 2019 Q2 | 96.35 Million SGD | 1.11% |
| 2019 Q3 | 96.02 Million SGD | -0.35% |
| 2018 Q2 | 96.74 Million SGD | 1.29% |
| 2018 FY | 88.92 Million SGD | -8.08% |
| 2018 Q4 | 88.92 Million SGD | 0.06% |
| 2018 Q3 | 88.87 Million SGD | -8.14% |
| 2018 Q1 | 95.51 Million SGD | 27.72% |
| 2017 Q4 | 74.78 Million SGD | 2.43% |
| 2017 FY | 96.74 Million SGD | 31.8% |
| 2017 Q3 | 73 Million SGD | 7.48% |
| 2017 Q2 | 67.92 Million SGD | -5.92% |
| 2017 Q1 | 72.19 Million SGD | 2.23% |
| 2016 Q4 | 70.62 Million SGD | -49.16% |
| 2016 FY | 73.4 Million SGD | -46.74% |
| 2016 Q3 | 138.9 Million SGD | 0.79% |
| 2016 Q2 | 137.81 Million SGD | -4.18% |
| 2016 Q1 | 143.82 Million SGD | -6.68% |
| 2015 FY | 137.81 Million SGD | 8.51% |
| 2015 Q4 | 154.1 Million SGD | -12.12% |
| 2015 Q3 | 175.36 Million SGD | 2.54% |
| 2015 Q2 | 171.01 Million SGD | -1.11% |
| 2015 Q1 | 172.92 Million SGD | 1.69% |
| 2014 Q1 | 47.56 Million SGD | 1.38% |
| 2014 Q4 | 170.06 Million SGD | 231.72% |
| 2014 Q3 | 51.26 Million SGD | 3.75% |
| 2014 Q2 | 49.41 Million SGD | 3.88% |
| 2014 FY | 127 Million SGD | 157.02% |
| 2013 Q3 | 40.58 Million SGD | -5.37% |
| 2013 Q4 | 46.92 Million SGD | 15.61% |
| 2013 FY | 49.41 Million SGD | 15.22% |
| 2013 Q1 | 23.8 Million SGD | 3.57% |
| 2013 Q2 | 42.88 Million SGD | 80.14% |
| 2012 Q1 | 16.98 Million SGD | 0.0% |
| 2012 FY | 42.88 Million SGD | 123.32% |
| 2012 Q2 | 19.2 Million SGD | 13.06% |
| 2012 Q4 | 22.98 Million SGD | 4.19% |
| 2012 Q3 | 22.06 Million SGD | 14.88% |
| 2011 Q2 | 14.83 Million SGD | 0.0% |
| 2011 FY | 19.2 Million SGD | 29.43% |
| 2010 FY | 14.83 Million SGD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| American Bio Medica Corporation | 3.6 Million USD | -2472.201% |
| Arrayit Corporation | 7.49 Million USD | -1137.962% |
| Atlantic International Corp. | 3.82 Million USD | -2323.982% |
| Biocept, Inc. | 22.01 Million USD | -321.592% |
| Bioqual, Inc. | 18.93 Million USD | -390.047% |
| CardioGenics Holdings Inc | 1.79 Million USD | -5070.417% |
| DermTech, Inc. | 64.75 Million USD | -43.317% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 734.97 Million USD | 87.373% |
| HTG Molecular Diagnostics, Inc. | 12.38 Million USD | -649.276% |
| iMD Companies, Inc. | 1.67 Million USD | -5443.192% |
| IDenta Corp. | 1.01 Million USD | -9059.973% |
| Interpace Biosciences, Inc. | 28.15 Million USD | -229.598% |
| Integrative Health Technologies, Inc. | 297.94 Thousand USD | -31048.157% |
| InVitro International | 78.99 Thousand USD | -117389.556% |
| Lumos Diagnostics Holdings Limited | 19.72 Million USD | -370.399% |
| Many Bright Ideas Technologies Inc. | 129.29 Thousand USD | -71676.607% |
| Medical Imaging Corp. | 9.51 Million USD | -875.141% |
| NovelStem International Corp. | 4.2 Million USD | -2106.449% |
| Optigenex Inc. | 9.57 Million USD | -869.686% |
| PharmChem, Inc. | 558.64 Thousand USD | -16512.458% |
| Proteome Sciences plc | 18.48 Million USD | -401.946% |
| Response Genetics, Inc | 15.86 Million USD | -484.893% |
| Rennova Health, Inc. | 49.66 Million USD | -86.853% |
| RushNet, Inc. | 6.23 Million USD | -1387.5% |
| ScreenPro Security Inc. | 1.6 Million USD | -5698.185% |
| Stella Diagnostics Inc. | 18 Million USD | -415.429% |
| StageZero Life Sciences Ltd. | 8.2 Million USD | -1031.218% |
| Todos Medical Ltd. | 50.15 Million USD | -85.029% |